• Vitaspring Biomedical posted a net loss of USD 415,368 for the year ended Jan. 31, 2026, narrowing from USD 774,922 a year earlier.
• Operating loss narrowed to USD 385,411 as operating expenses fell to USD 385,411 from USD 679,914.
• Revenue was unchanged at no revenue.
• Working capital deficiency widened to USD 4.43 million, with current liabilities rising to USD 4.45 million.
• Management said it expects additional capital will be required over the next 12 months and is exploring equity or debt financing and strategic partnerships.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vitaspring Biomedical Co. Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001640334-26-001082), on June 17, 2026, and is solely responsible for the information contained therein.